May 15, 2020
Ono Pharmaceutical said on May 14 that it has submitted an application for its PD-1 inhibitor Opdivo (nivolumab) to expand its use for the treatment of previously untreated, unresectable, advanced, or recurrent gastric cancer. If approved, the drug will offer...read more